RefinedPractice
EQ-5D Index Clustering: Causes and Implications for Health Care
5 February 2013
In a paper presented at the January 2013 Health Economics Study Group meeting, David Parkin of the NHS and OHE’s Nancy Devlin and Yan Feng examined…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer…
Overview of the OHE Study on the Cost of Drug Development Presented
29 January 2013
OHE’s Jorge Mestre-Ferrandiz reviewed the results of OHE’s recent study on the R&D cost of developing a new drug at a seminar at University College London.…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
New requirements for health technology assessment in Europe have important implications for markets and for access to new medicines. At a recent conference, OHE’s Jorge Mestre-Ferrandiz…
Join OHE on Twitter, LinkedIn and SlideShare
21 January 2013
Keeping up with the latest important information is a constant challenge — made both easier and more difficult by the explosion in communication avenues. To ensure…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
Jorge Mestre-Ferrandiz, lead author on OHE’s recent report on the cost of developing new drugs, will be discussing the important cost drivers at an upcoming UCL…
New Pilot Study: Capturing Public Preferences about Health Care Priorities
16 January 2013
The proposals from the UK Department of Health (DH) for value based pricing (VBP) include a process whereby higher prices would be granted to medicines that…
Spotlight on OHE: Making Health Care Choices and Decisions
7 January 2013
OHE’s research and consulting captures a range of key issues that affect how health care systems are organised and how decisions are made within them. For…
